Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-559 in advanced solid tumors and molecularly defined cancers
NCT06625515Phase 1Terminated
- Sponsor
- Accent Therapeutics
- Start
- Oct 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ATX-559 in solid tumor (advanced stage), breast cancer, colorectal cancer (CRC) and 3 more (3 arms), sponsored by Accent Therapeutics. Primary endpoints: Recommended phase 2 dose and/or maximum tolerated dose at 12 months and Safety and tolerability of ATX-559 at 12 months. Started Oct 2024; status: terminated.
02
Drugs
ATX-559
03
Conditions
solid tumor (advanced stage)breast cancercolorectal cancer (CRC)colon cancerrectal adenocarcinoma
Beyond the preview
Go deeper on NCT06625515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625515.